Integer Holdings ITGR Cardiac Rhythm Management & Neuromodulation — Sales
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Integer Holdings in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Integer Holdings’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Integer Holdings's cardiac rhythm management & neuromodulation — sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Integer Holdings's cardiac rhythm management & neuromodulation — sales?
- Integer Holdings (ITGR) reported cardiac rhythm management & neuromodulation — sales of $168.26M in Q1 2026.
- How has Integer Holdings's cardiac rhythm management & neuromodulation — sales changed year-over-year?
- Integer Holdings's cardiac rhythm management & neuromodulation — sales increased by 4.9% year-over-year, from $160.35M to $168.26M.
- What is the long-term trend for Integer Holdings's cardiac rhythm management & neuromodulation — sales?
- Over 4 years (2021 to 2025), Integer Holdings's cardiac rhythm management & neuromodulation — sales has grown at a 7.4% compound annual growth rate (CAGR), from $502.29M to $668.8M.
- What does cardiac rhythm management & neuromodulation — sales mean?
- This metric measures the net revenue attributable to the Cardiac Rhythm Management and Neuromodulation business segment. It serves as a primary indicator of the segment's ability to convert its specialized manufacturing capabilities into top-line financial performance within the medical device industry. By isolating these sales, stakeholders can evaluate the operational scale and revenue contribution of these specific therapeutic product categories.